Bispecific antibodies against CT-RCC herv-e

Ended Purchase Order Awarded Last action

Contract number
75N92024P00043
Awardee
Awarding agency
Obligated
$51,836

Award facts

Contract value 100% obligated
$51,836.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC
Q301 Reference Laboratory Testing
Set-aside
No set-aside
Competition
Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Australia

Award details come from SAM.gov/FPDS.

About this award

Written by GovTribe AI ·

The Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute awarded a $51,836 firm fixed price purchase order to Myrio Therapeutics PTY LTD of Australia. The contract is for the delivery of bispecific antibodies against CT-RCC HERV-E, to be completed by April 1, 2024. No set-aside designation was used for this award made on February 1, 2024. The place of performance is Australia. The National Heart Lung and Blood Institute funds research into heart, lung, blood, and sleep disorders and this contract will provide antibodies for potential use in that research.

Quick answers

Who was awarded contract 75N92024P00043?

75N92024P00043 was awarded to Myrio Therapeutics PTY LTD by National Heart Lung and Blood Institute (National Institutes of Health) on February 1, 2024.

How much is contract 75N92024P00043 worth?

The government has obligated $51,836 on 75N92024P00043.

Was contract 75N92024P00043 competed?

The extent of competition for 75N92024P00043 was competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login